Regeneus’s world tour continues as it secures Euro patent
Special Report: Regenerative medicine company Regeneus has secured another key patent win as it looks to bring its anti-inflammatory treatment to more markets around the world.
The company (ASX:RGS) told investors this morning that it had secured a European patent, providing the commercial rights to Progenza across 38 European member states, including the UK, Germany, France and Italy, until early 2032.
Progenza was developed for the treatment of osteoarthritis and other musculoskeletal diseases as well as other inflammatory diseases that have limited treatment options.
It can be made for a mass market from a single person’s stem cells.
Regeneus has been on a world tour of late, securing Progenza patents in key markets.
Earlier this year, it secured commercial rights in the US and also holds patents in Australia, New Zealand, and Japan, providing significant commercial protection in some of the world’s largest regenerative medicine markets.
“This is a significant milestone for Progenza, granting us with further protection of our commercial rights over the Progenza technology platform.
“The addition of patent protection for the European market delivers another key milestone as we look to bring Progenza to the Europe and other key markets,” said Regeneus CEO John Martin.
The World Intellectual Property Organisation (WIPO) says it’s important for biotechs to patent their work.
Research and development can sometimes eat up 40 to 50 per cent of revenue and patents enable companies to benefit from their work for a period of time.
Regeneus has more than 70 patents or patent applications on the go.
Its product pipeline also includes a cancer vaccine and a topical cream for inflammatory skin conditions.
Regeneus is a Stockhead advertiser.